RxDoctor Payments Data

Min Wei Lee, MD

Dermatology · Walnut Creek, CANPI 1124014741

Payments from drug & device makers

$236,672in general payments, 2019–2025

Across 41 payments — averaging $5772.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$144K
  • E.r. Squibb & Sons, L.L.C.$93K
  • Genentech USA, Inc.$131
  • Pfizer$93
  • AbbVie$69
  • Arcutis Biotherapeutics, Inc.$28
  • plus $59 from 3 others
$7,245in research payments, 2019–2025

Across 1 payment — averaging $7245.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

What the payments were for

  • Food & beverage$35092%
  • Education$318%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly10$143,567
E.r. Squibb & Sons, L.L.C.13$92,724
Genentech USA, Inc.6$131
Pfizer5$93
AbbVie3$69
Arcutis Biotherapeutics, Inc.1$28
VYNE Pharmaceuticals Inc.1$22
Novartis1$20
Strata Skin Sciences, Inc.1$16

How this compares

$236,672 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$865,204
Medicare patients
573
Services billed
7,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clindamycin Phosphate11$377
Mupirocin46$306

Paid to pharmacies, not to this prescriber.

Other dermatology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →